For the fiscal year ending December 2025, consolidated revenue was JPY 26,840 million (up 13.7% YoY), operating loss was JPY 3,471 million, and net loss attributable to owners of parent was JPY 4,244 million. Total assets increased to JPY 83,791 million and total equity rose to JPY 51,842 million.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2160","jir_company_name":"GNI Group, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-03-04","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/03\/2160-20260304-01.pdf","jir_short_summary":"For the fiscal year ending December 2025, consolidated revenue was JPY 26,840 million (up 13.7% YoY), operating loss was JPY 3,471 million, and net loss attributable to owners of parent was JPY 4,244 million. Total assets increased to JPY 83,791 million and total equity rose to JPY 51,842 million.","jir_summary":"### Overview of Performance\nIn the consolidated fiscal year ending December 2025, revenue increased to JPY 26,840 million (up 13.7% YoY), but the company recorded an operating loss of JPY 3,471 million and a net loss attributable to owners of parent of JPY 4,244 million. Pharmaceutical business revenue increased to JPY 19,158 million (up 4.7% YoY), but profits were pressured by increased stock-based compensation expenses and a reversal decline in foreign exchange gains related to the settlement of long-term loans to affiliates in the previous consolidated fiscal year. The medical devices business achieved significant revenue growth to JPY 7,681 million (up 44.7% YoY) and recorded an operating profit of JPY 533 million. Total assets strengthened to JPY 83,791 million (up 16.5% YoY) and total equity rose to JPY 51,842 million (up 30.5% YoY), reinforcing the financial base.\n\n### Outlook\nFor fiscal year 2026, steady revenue and profit growth are expected in both the pharmaceutical and medical device businesses. In particular, the pharmaceutical business plans NDA submission of new drug candidate F351 in China and the start of clinical trials in the U.S. The Medtech business anticipates increased revenue and profit from new product launches and the acquisition effect of ZOO LABO. However, due to uncertainties such as the timing of F351 approval, pricing, and R&D progress at Cullgen, earnings forecasts are not disclosed at this time.","jir_financial_highlights":"Revenue: JPY 26,840 million (Up 13.7% YoY)\nOperating Income: Loss of JPY 3,471 million (Turned negative from a profit of JPY 1,402 million the previous year)\nProfit Before Tax: Loss of JPY 4,634 million (Turned negative from a profit of JPY 238 million the previous year)\nNet Income Attributable to Owners of Parent: Loss of JPY 4,244 million (Turned negative from a profit of JPY 1,098 million the previous year)\nTotal Assets: JPY 83,791 million (Up 16.5% YoY)\nTotal Equity: JPY 51,842 million (Up 30.5% YoY)\nAverage Number of Outstanding Common Shares: 52,464,827 shares (Increase from 50,007,923 shares the previous year)\nDividend: JPY 0.00 (Year-end) (No dividend, same as previous year)","jir_category":"","jir_hashtags":"#GNIGroupInc, #FinancialSummary, #financial_summary, #JapaneseStocks","jir_key_figures":"Revenue: JPY 26,840 million (up 13.7% YoY)\nNet Income Attributable to Owners of Parent: Loss of JPY 4,244 million (Profit of JPY 1,098 million previous year)\nTotal Equity: JPY 51,842 million (up 30.5% YoY)","jir_meta_title":"GNI Group, Inc. Financial Summary for Fiscal Year Ending December 2025\uff5cRevenue JPY 26,840 million, Operating Loss JPY 3,471 million","jir_meta_description":"Financial summary of GNI Group, Inc. for fiscal year ending December 2025. Revenue was JPY 26,840 million (up 13.7% YoY), operating loss JPY 3,471 million, and net loss attributable to owners of parent JPY 4,244 million. Total equity grew to JPY 51,842 million. Includes earnings outlook for 2026.","jir_og_title":"GNI Group Financial Summary Announcement for Fiscal Year Ending December 2025","jir_og_description":"Revenue of JPY 26,840 million, operating loss of JPY 3,471 million. Latest financial update including 2026 outlook.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Revenue Trend (million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal Year Ending December 2024\\\",\\\"Fiscal Year Ending December 2025\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[23611,26840],\\\"backgroundColor\\\":\\\"#4e79a7\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Income Trend (million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal Year Ending December 2024\\\",\\\"Fiscal Year Ending December 2025\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[1402,-3471],\\\"backgroundColor\\\":[\\\"#4e79a7\\\",\\\"#e15759\\\"]}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":false}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent Trend (million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal Year Ending December 2024\\\",\\\"Fiscal Year Ending December 2025\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income Attributable to Owners of Parent\\\",\\\"data\\\":[1098,-4244],\\\"backgroundColor\\\":[\\\"#4e79a7\\\",\\\"#e15759\\\"]}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":false}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Revenue Composition by Segment for Fiscal Year Ending December 2025\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Pharmaceutical Business\\\",\\\"Medical Devices Business\\\"],\\\"datasets\\\":[{\\\"data\\\":[19158,7681],\\\"backgroundColor\\\":[\\\"#4e79a7\\\",\\\"#f28e2b\\\"]}]}}\"}, {\"jir_chart_id\": \"capital_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Total Equity Trend (million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal Year Ending December 2024\\\",\\\"Fiscal Year Ending December 2025\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Total Equity\\\",\\\"data\\\":[39713,51842],\\\"backgroundColor\\\":\\\"#4e79a7\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":9370,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-33252","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n